Eli Lilly investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales ...

Novo Nordisk's 2024 earnings exceeded estimates, with strong performance in diabetes, obesity, and rare disease segments.

Eli Lilly reported mixed fourth-quarter results on Thursday, surpassing earnings expectations but falling short of sales ...

Nephrologists jumped on the GLP-1 bandwagon well before Novo Nordisk won FDA approval for Ozempic in chronic kidney disease ...

Market report delivers crucial insights into the market's growth trajectory and the primary revenue drivers anticipated ...

Top stock picks for capital appreciation and outperformance, with a focus on profits, dividends, and long-term viability.

As the first earnings season of 2025 unfolds, investors are likely analyzing financial reports to refine their portfolio strategies.

Our assumptions for overall biopharma GLP-1 sales in 2031 surpass $200 billion across diabetes, obesity, and overweight patients with Lilly capturing $75 billion of the market. We think more than ...

On an adjusted basis, the U.S. drugmaker expects to earn between $22.50 and $24.00 per share in 2025. Analysts were expecting ...

Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...

The results were consistent with the preliminary results Eli Lilly shared in January, which disappointed investors.

Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the drugmaker came out with a mostly better-than-expected 2025 forecast.